Myosin Ih inhibitors are a class of chemical compounds that specifically target and inhibit the function of Myosin Ih, a member of the unconventional myosin family. Myosin proteins are motor proteins that convert chemical energy, typically from ATP, into mechanical work, allowing them to move along actin filaments. While conventional myosins are primarily involved in muscle contraction, unconventional myosins like Myosin Ih play essential roles in various non-muscle cellular processes. Myosin Ih is involved in functions such as intracellular transport, actin cytoskeleton remodeling, and endocytosis. It achieves these tasks by interacting with actin filaments and moving along them, transporting cargo and helping to organize the cytoskeleton. Inhibitors of Myosin Ih function by binding to key regions of the protein, such as its motor domain, and interfering with its ATPase activity or its interaction with actin filaments, effectively preventing it from executing its mechanical and transport functions.
Inhibiting Myosin Ih can lead to disruptions in processes that rely on actin-based motility and intracellular transport. By blocking Myosin Ih's ability to interact with actin and perform its motor functions, these inhibitors can impact critical cellular activities such as the movement of vesicles, the organization of the actin cytoskeleton, and membrane dynamics, including endocytosis and exocytosis. Researchers use Myosin Ih inhibitors to study the specific roles of this protein in various cellular contexts, particularly in relation to its contribution to actin dynamics and intracellular trafficking. These inhibitors also provide valuable insights into the broader roles of unconventional myosins in cellular function and organization, helping scientists understand how these proteins influence processes like cell shape maintenance, signal transduction, and membrane organization. By studying Myosin Ih inhibitors, researchers can gain a deeper understanding of the complex molecular mechanisms governing intracellular movement and cytoskeletal regulation, contributing to a broader knowledge of cellular dynamics and organization.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
This histone deacetylase inhibitor could lead to a less accessible chromatin state at the Myosin Ih locus, thereby reducing transcription initiation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As a DNA methyltransferase inhibitor, this agent could decrease methylation marks that typically suppress Myosin Ih gene expression, potentially leading to its downregulation. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D could intercalate into DNA at the Myosin Ih gene, blocking RNA polymerase progression and thus inhibiting mRNA synthesis. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
This translation elongation inhibitor might block the elongation step of Myosin Ih mRNA translation, leading to a decrease in protein production. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By specifically inhibiting mTOR, this compound could decrease the initiation of cap-dependent translation, potentially leading to reduced levels of Myosin Ih protein. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
As an inhibitor of RNA polymerase II, α-Amanitin could prevent the transcription of Myosin Ih mRNA, effectively decreasing protein synthesis. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Puromycin might cause premature chain termination during Myosin Ih protein synthesis, leading to truncated proteins that could be rapidly degraded. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
By disrupting endosomal acidification, Chloroquine could interfere with the degradation pathway of Myosin Ih, leading to an accumulation of dysfunctional protein and potentially triggering a decrease in its expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
This proteasome inhibitor could prevent the degradation of ubiquitinated Myosin Ih proteins, potentially resulting in a negative feedback loop that decreases its expression. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
This protein synthesis inhibitor could halt peptide bond formation on ribosomes, leading to a cessation of Myosin Ih protein production. |